Background
Parkinson’s disease (PD) is a complex neurodegenerative disease caused by a variety of factors. The incidence in the population over the age of 65 is about 1.8% [
1]. The major clinical features of PD include resting tremor, bradykinesia and rigidity [
2]. The pathological features of PD include progressive loss of dopaminergic neurons from the substantia nigra pars compacta and the presence of intercellular Lewy bodies in surviving neurons [
3]. The cause of PD is unclear, but it is generally considered to be associated with the impairment in degradation of ubiquitin proteasome system (UPS), mitochondrial dysfunction, and oxidative stress [
4‐
6]. We hypothesize that genetic and environmental factors and aging together lead to the development of PD. In this study, we investigated five genes, including
SNCA,
LRRK2,
PARK2,
SLC41A1, and
NOD2, all of which might be involved in the cytological mechanisms of neurodegeneration disease aiming to identify genetic variants associated with sporadic PD in Chinese patients and understand the genetic etiology of PD.
The first gene to be identified as associated with PD was
SNCA (
PARK1/4), which encodes α-synuclein. The major mutations in
SNCA include A53T, A30P, and E46K [
7‐
9]. Although these mutations account for less than 1% of the cases, patients carrying these mutations have obviously clinical phenotypes [
8]. The A53T and A30P mutations have been found in Chinese patients with sporadic PD [
10]. However, the association of E46K with sporadic PD has not been reported in Chinese patients.
LRRK2 (
PARK8) encodes a large protein containing five functional domains, involved in a number of physiological functions, including substrate binding, protein phosphorylation and protein interactions [
11]. The most common mutation G2019 of
LRRK2 in European populations presents less than 0.1% in Asian individuals [
12]. The G2385R was at a significantly higher frequency in Asian patients than in controls [
13]. One of the purposes of this study is to re-validate this variant in southern China. In addition, Yue Huang found A1442P in pedigrees of the Australian patients and considered it pathogenic, because it is conserved across many species and a substitution of Ala with Pro can change the secondary structure of proteins [
14]. However, A1442P has not been further confirmed from a large number of cases and other populations.
The most common cause of young-onset sporadic PD is autosomal recessive
PARK2 mutation [
15]. The E3 ubiquitin ligase, parkin, which is encoded by
PARK2, can specifically degrade UPS through tagging ubiquitin on protein [
16]. Exon deletion, insertion, and point mutations in
PARK2 have been found in different ethnic groups [
17]. In 2009, Yih-Ru Wu screened 506 Taiwan sporadic patients with age of onset below 50 years for
PARK2 gene mutation and identified a novel IVS9 insertion (c.1084intron
+) [
18]. The c.1084intron
+ was due to a G > A polymorphism at position −6 of a cryptic splice acceptor site within IVS9.
In recent years, genome-wide association studies (GWAS) have identified a number of new susceptibility loci associated with PD in different ethnic groups. Of these loci, the most striking locus is
PARK16, which is located in 1q23 and contains 5 genes (
SLC45A3,
NUCKS1,
RAB7L1,
SLC41A1, and
PM20D1) [
19].
SLC41A1 encodes a 56 kDa Mg
2+ transporter consisting of 513 amino acids, it has been proposed that PD might be associated with lack of Ca
2+ and Mg
2+ in the brain [
20]. In 2010, Arianna Tucci sequenced
PARK16 in 182 patients with PD in the United Kingdom and found A350V in
SLC41A1, but failed to detect it in a large series of ethnicity-matched controls (n = 483) [
19]. To inspect whether this coding mutations may or may not be the disease-causing mutation, we aim to screen A350V in Chinese Han populations.
Several obtained findings suggest that inflammation also contributes to the pathogenesis of PD [
21‐
23]. It has been reported that the G174C variant in the
IL-6 promoter may influence the risk for developing PD, particularly regarding early age of onset PD [
24]. Recent studies revealed that NF-κB-mediated inflammation might also play an important role in the pathogenesis of PD [
25,
26]. NOD (nucleotide-binding oligomerization domain) proteins, i.e. NOD1 (a product of
CARD4 gene) and NOD2 (encoded by
NOD2), are intracellular signaling molecules that recognize bacterial components, mediate the activation of NF-κB and induce or enhance apoptosis [
27]. In 2007, Monika Bialecka et al. screened 308 Portland patients for 3 variants (R702W, G908R, and 1007fs) in
NOD2 which were associated with Crohn’s disease (CD) in Europeans. They found that
NOD2 might be associated with susceptibility to PD [
28]. Although inflammatory response has long been considered as one of the factors for PD development, it has not yet been reported that R702W, G908R, 1007fs and P268S in
NOD2 is associated with Chinese PD patients.
In this study, we screened 237 patients with sporadic PD and 190 controls for the 9 variants, E46K (rs104893875), G2385R (rs34778348), A1442P, IVS9, A350V, R702W (rs2066844), G908R (rs2066845), 1007fs (rs2066847) and P268S (rs2066842), in 5 genes which are possibly found to be associated with Chinese PD patients, including SNCA, LRRK2, PARK2, SLC41A1, and NOD2. These variants included both rare mutations (e.g. E46K and A1442P) and SNPs, so we also screened them in a pedigree with two PD cases. In this way, we aimed to provide references for the study of disease-causing or susceptibility gene for PD. In addition, using the overlap extension polymerase chain reaction (PCR)-based site-directed mutagenesis, we constructed wild-type and homozygous mutant plasmids for these variants, which were used as controls to determine variants in this study.
Discussion
Gene polymorphism is a risk factor of PD, and it shows different distributions in different ethnic groups and geographies. Although GWAS have identified a number of susceptibility genes and relevant variants associated with PD in different populations, few of them have been analyzed in other populations. To best of out knowledge, we first screened 8 variants that have been associated with neurodegeneration, E46K, A1442P, A350V, IVS9, P268S, R702W, G908R, and 1007fs in Chinese populations, and further verified the presence of the high-frequency variant G2385R in southern China.
In case–control study, both PD patients and controls carried the heterozygous G2385R mutation, and the genotype difference was slightly significant. This is consistent with the results of a previous study of 600 Chinese PD patients and 334 controls [
30]. This variant was initially reported by Xingkai An. in 2008 among PD patients in Sichuan area [
30]. However, we did not find E46K, A1442P, or A350V variants in patients with PD and in controls. All of them indicated following phenomenon: the ancestry effect; familial PD results from rare, highly penetrant pathogenic mutation (e.g. E46K, A1442P); multiple variants of low penetrant (e.g. A350V) contribute to the risk of PD and are involved in the etiology of PD.
Interestingly, none of homozygosity of these variants was found in either the case or control groups [
31,
32]. It was reported that heterozygosity of autosomal recessive genes was very important in the initiation and development of PD. For example, it has been found that patients with PD who carry heterozygous
PARK2 and
PINK1 mutations have an age of onset between that of wild-type individuals and patients with homozygous mutations [
33,
34]. Heterozygous mutation carriers indeed show preclinical changes at the metabolic, structural, or functional levels that are detectable by modern techniques of neuroimaging and electrophysiology. Heterozygosity for putative recessive mutations could lead to disease expression by at least three mechanisms which are haploinsuffciency, dominant-negative effect and novel gain-of-function [
35]. Taken together, heterozygous mutations in putative recessive genes seem to increase the susceptibility to develop PD.
The new insertion mutation, c.1084intron
+ in
PARK2, introduces two new amino acids and a TAA stop codon, resulting in reduced levels of parkin protein [
36]. This insertion mutation may be associated with the -6G > A polymorphism of intron 9 in
PARK2. One case–control study found IVS9G > A to be a risk factor of PD in Taiwan. A functional study of IVS9G > A by Guey-Jen Lee-Chen showed that the shear efficiency of -6A was slower than that of -6G at the protein level [
37]. 12.7% PD patients and 7.9% controls carried the heterozygous IVS9 mutation, but the allele difference and genotype difference were not statistically significant. This result is consistent with the results of a previous study of 506 patients and 508 controls in Taiwan [
18]. Further investigation into the association between IVS9G > A and PD need, through larger sample size from various populations.
Inflammation is one of the suspected theories of PD. The activation of NF-κB and microglial cells around dopaminergic neurons have been analyzed in patients with PD [
38]. In 2007, Monika Bialecka reported that three variants (R702W, G908R, and L1007fsinsC) of
NOD2 encoding NOD2, a protein that can activate the apoptosis response, were significantly associated with PD in a Polish population [
28]. It has been demonstrated that these three variants are not associated with CD in Chinese Han, Korean, and Japanese populations [
39‐
42]. Similarly, these three common SNPs (R702W, G908R, and 1007fs) were not detected in our cohort. However, a novel variant P268S was observed, which has also been discovered to be associated with CD in Chinese population [
43]. Although linkage disequilibrium was observed between P268S and the other three SNPs in
NOD2, only P268S of the four variants was slightly significant in our study, which was consistent with recent study suggesting that P268S instead of 1007fs, G908R, R702W was a risk factor of Chinese Crohn’s disease population. It indicated that P268S may be one of risk factors for PD in Chinese individuals, or the P268S variant may be in linkage disequilibrium with another causal rare variant on
NOD2 gene. The frequencies of minor allele 1007fs, G908R, R702W and P268S variants are much lower in Asians compare to Caucasians populations. In this study, genotype frequency of P268S (
P = 0.0450) had slightly significant differences. The sample size has to be very large or odds ratio has to be very high to have enough power for detection effect of very rare variants.
NOD2 is a member of the Apaf-1 superfamily of apoptosis regulators that is expressed in monocytes and involved in the activation of NF-κB, by bacterial component muramyl dipeptide (MDP) [
44]. Functional studies revealed that both normal and P268S NOD2 induced similar levels of NF-κB activation in response to MDP [
45] and the G908R, R702W, and L1007fsinsC variants in the presence and absence of P268S are defective in their ability to respond to bacterial lipopolysaccharides and peptidoglycan, whereas P268S alone exhibited wild-type activity [
46]. Thus, P268S was confirmed as the haplotype background of these three variants but has no influence on functions of the CD-associated variants of
NOD2[
47]. Notably, above results from NF-κB activation assay using human embryonic kidney (HEK) 293 cell lines, but the function activity of NOD2 in neurodegeneration field remain unclear. Additionally, Crane et al. found that carriage of the P268S variant was associated with greater disease activity and inversely associated with ulcerative colitis spondylarthritis [
48]. We regarded the P268S of
NOD2 behaving as a common factor of PD and CD. Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract, which is thought to result from the effect of environmental factors in a genetically predisposed host [
49]. A wealth of new information has emerged to suggest that inflammation-derived oxidative stress and cytokine dependent toxicity may contribute to nigrostriatal pathway degeneration and hasten progression of disease in humans with idiopathic PD. Both them suggest that inflammation may play a role connecting between PD and CD.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
QLM, XKA, and QL collected the blood samples from PD patients and controls, extracted genomic DNA, and searched relevant literature. ZML performed PCR, RFLP, and CE analysis and built positive and negative control plasmids. HJZ and LLC designed the primers for PCR, cloning, and site-directed mutagenesis and performed sequence alignment. WQH and PH participated in statistical analysis and the production of tables. CMT designed all the experiments and drafted the manuscript. All authors read and approved the final manuscript.